This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
4 - 6 June, 2024
Excel London Platinum Suite

Mark Aspinall-O'Dea, PhD
Associate Director - Discovery at Charles River


First author on several peer-reviewed papers, Mark Aspinall-O’Dea is Associate Director in Biotherapeutics at Charles River. Mark's scientific experience includes 10 years of postdoctoral research in clinical and academic settings, and more than 10 years of commercial experience in the biopharmaceutical field. Mark currently leads a large research team focused on the Retrogenix cell microarray platform and future technology developments.

Agenda Sessions

  • Antibody Discovery Platform for IND Enabling Studies